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OBJECTIVES The purpose of this study was to evaluate the relationship between body mass index (BMI),
including low BMIs, and endothelial function.
BACKGROUND Epidemiologic study has demonstrated that not only obesity but also a low BMI may be a risk
factor for cardiovascular disease.
METHODS The forearm blood flow (FBF) response to acetylcholine (ACh) and isosorbide dinitrate
(ISDN) was measured in 87 healthy young men (15 low BMI, 51 normal, 14 obese, and 7
extremely obese).
RESULTS Plasma concentrations of 8-hydroxy-2-deoxyguanosine and serum concentrations of
malondialdehyde-modified low-density lipoprotein were higher in low BMI, obese, and
extremely obese subjects than in normal subjects and were similar among the low BMI, obese,
and extremely obese groups. The FBF response to ACh was greater in the normal group than
in the other groups (p  0.001), and was lower in the extremely obese group as compared
with the other groups (p 0.001). The ACh-stimulated vasodilation was similar between the
low BMI group and the obese group. The ISDN-stimulated vasodilation was similar in all
four groups. There were no significant differences in ACh-stimulated vasodilation between
the four groups after the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine
infusion. Co-infusion of vitamin C augmented the FBF response to ACh in low BMI, obese,
and extremely obese groups—but not in normal BMI group.
CONCLUSIONS These findings suggest that not only obesity but also a low BMI may be a risk factor for
impaired endothelium-dependent vasodilation through the increased oxidative stress, leading
to the reduced bioavailability of NO. (J Am Coll Cardiol 2003;42:256–63) © 2003 by the
American College of Cardiology Foundation
Nitric oxide (NO) plays an important role in the regulation
of vascular tone, inhibition of platelet aggregation and
adhesion, and suppression of smooth muscle cell prolifera-
tion (1–3). Obesity is associated with the alteration of NO
release from vascular endothelium (4,5). Several investiga-
tors, including ourselves, have shown that endothelium-
dependent vasodilation of forearm and leg circulation is
impaired in obese individuals compared with lean individ-
uals (6,7). Large epidemiologic studies have shown that
obesity is a risk factor for cardiovascular disease (8). There-
fore, reduced NO bioavailability may, at least in part,
contribute to the obesity-induced cardiovascular complica-
tions.
On the other hand, in studies that demonstrate endothe-
lial dysfunction in obese individuals but not lean individuals,
few or no low body mass index (BMI) subjects are included
in the lean group. Epidemiologic study has demonstrated
that subjects who have a BMI of 22.2 kg/m2 have the lowest
morbidity, suggesting that there is a J-curve phenomenon
between prevalence of disease, including cardiovascular
complications, and BMI (9). These findings suggest that
not only obesity but also a low BMI may be a risk factor for
cardiovascular disease. There is little information concern-
ing the relationship between a low BMI and endothelial
function.
Therefore, we evaluated the endothelium-dependent va-
sodilation induced by acetylcholine (ACh), and the
endothelium-independent vasodilation induced by isosor-
bide dinitrate (ISDN), in low BMI individuals without a
history of smoking, hypertension, hypercholesterolemia,
diabetes mellitus, or renal dysfunction.
METHODS
Subjects. We studied 15 extremely low BMI healthy men
(mean age, 29  6 years), 51 normal BMI healthy men
(mean age, 27  5 years), 14 obese healthy men (mean age,
28  4 years), and 7 extremely obese healthy men (mean
age, 29  7 years). Low BMI was defined as 18.5 kg/m2,
normal as 18.5 to 25 kg/m2, obesity as 25 to 30
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kg/m2, and extremely obesity as 30 kg/m2. Subjects with
a history of cardiovascular or cerebrovascular disease, hyper-
tension, hypercholesterolemia, diabetes mellitus, liver dis-
ease, renal disease, or smoking were excluded. The study
protocol was approved by the ethics committee of the
Hiroshima University Faculty of Medicine. Informed con-
sent was obtained from all study participants.
Measurement of forearm blood flow. Forearm blood flow
(FBF) was measured using a mercury-filled Silastic strain-
gauge plethysmography (EC-5R, D.E. Hokanson, Inc.,
Bellevue, Washington) as previously described (10,11).
Briefly, a strain-gauge was attached to the upper part of the
left arm and connected to a plethysmography device and was
supported above the right atrium. A wrist cuff was inflated
to a pressure of 50 mm Hg above the systolic blood pressure
(BP) to exclude the hand circulation from the measurements
1 min before each measurement and throughout the mea-
surement of FBF. The upper arm congesting cuff was
inflated to 40 mm Hg for 7 s in each 15-s cycle to occlude
venous outflow from the arm using a rapid cuff inflator
(EC-20, D.E. Hokanson, Inc.). The FBF output signal was
transmitted to a recorder (U-228, Advance Co., Nagoya,
Japan); FBF was expressed as mL per minute per 100 ml of
forearm tissue volume. Four plethysmographic measure-
ments were averaged for analysis of FBF at baseline and
during administration of drugs. Forearm vascular resistance
was calculated as the mean arterial pressure divided by FBF.
Study protocol. Forearm vascular responses to ACh (Daii-
chi Pharmaceutical Co., Tokyo, Japan) or ISDN (Eisai
Pharmaceutical Co., Tokyo, Japan) were evaluated in all
subjects. The study began at 8:30 AM. Subjects fasted the
previous night for at least 12 h. They were kept in the
supine position in a quiet, dark, air-conditioned room
(constant temperature 22°C to 25°C) throughout the study.
A 23-gauge polyethylene catheter (Hakkow Co., Tokyo,
Japan) was inserted under local anesthesia (1% lidocaine)
into the left brachial artery for the infusion of ACh and
ISDN and for the recording of arterial pressure with an
AP-641G pressure transducer (Nihon Kohden Co., Tokyo,
Japan). Another catheter was inserted into the left antecu-
bital vein to obtain blood samples.
After the subjects were placed in the supine position for
30 min, FBF and arterial BP were measured. Next, the
effects of ACh and ISDN on forearm hemodynamics were
studied; ACh (3.75, 7.5, and 15 g/min) and ISDN (0.75,
1.5, and 3.0 g/min) were infused intra-arterially for 5 min
at each dose using a constant rate infusion pump (Terfusion
STG-523, Termo Co., Tokyo, Japan). The FBF was
measured during the last 2 min of the infusion. Infusions of
ACh and ISDN were carried out in a random order. Each
study proceeded after the FBF had returned to baseline.
Furthermore, after a 30-min rest period, NG-monomethyl-
L-arginine (L-NMMA, CLINALFA Co., La¨ufelfingen,
Switzerland), an inhibitor of NO synthase, was infused
intra-arterially at a dose of 8 mol/min for 5 min while basal
FBF and arterial BP were recorded. After L-NMMA
infusion was complete, ACh (3.75, 7.5, and 15 g/min) was
administered.
To assess the effect of oxidative stress on endothelium-
dependence, we infused ACh in the presence of antioxidant,
vitamin C (Fuso Pharmaceutical Co., Osaka, Japan) in 7 of
the 15 low BMI subjects (mean age, 29  7 years), in 10 of
the 51 normal BMI subjects (mean age, 28  6 years), in 7
of the 14 obese subjects (mean age, 29  5 years), and in 5
of the 7 extremely obese subjects (mean age, 30  8 years).
The forearm vascular responses to ACh alone and in
combination with vitamin C (24 mg/min) were evaluated
using a protocol identical to this study protocol.
Forearm blood flow was calculated from the linear por-
tions of plethysmographic recordings by two independent
observers blinded to the study protocol. The intraobserver
coefficient of variation was 3.4%. We confirmed the repro-
ducibility of FBF response to ACh and ISDN in eight
healthy males (mean age, 25  4 years) on two separate
occasions. The coefficients of variation were 6.2% and 4.7%,
respectively.
Analytical methods. Samples of venous blood were placed
in tubes containing EDTA-Na (1 mg/ml) and in polysty-
rene tubes. The EDTA-containing tubes were chilled
promptly in an ice bath. Plasma was separated immediately
by centrifugation at 3,100 rpm at 4°C for 10 min, and serum
at 1,000 rpm (at room temperature) for 10 min. Samples
were stored at 80°C until assayed. Routine chemical
methods were used to determine serum concentrations of
total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, triglycerides, creatinine,
glucose, insulin, and electrolytes. The 8-hydroxy-2-
deoxyguanosine (8-OHdG), a marker of oxidative deoxyri-
bonucleic acid (DNA) damage, were measured by enzyme-
linked immunosorbent assay using high-sensitive 8-OHdG
assay kits (Nihon Yushi Co., Tokyo, Japan). The serum
concentrations of malondialdehyde-modified low-density
lipoprotein (MDA-LDL) also were assayed by ELISA
(anti-MDA-LDL antibody, SRL Co., Tachikawa, Tokyo,
Japan). Plasma concentrations of nitrate/nitrite (NOx) were
assayed by colorimetric methods using NOx assay kits
(Cayman Chemical Co., Ann Arbor, Michigan). Plasma
Abbreviations and Acronyms
ACh  acetylcholine
BMI  body mass index
BP  blood pressure
DNA  deoxyribonucleic acid
FBF  forearm blood flow
HOMA  homeostatic model assessment
ISDN  isosorbide dinitrate
L-NMMA  NG-monomethyl-L-arginine
MDA-LDL  malondialdehyde-modified low-density
lipoprotein
NO  nitric oxide
NOx  nitrate/nitrite
8-OHdG  8-hydroxy-2-deoxyguanosine
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concentrations of angiotensin II and endothelin-1 were
assayed by radioimmunoassay. Plasma concentrations of
norepinephrine were measured by high-performance liquid
chromatography. Fasting concentrations of insulin and glu-
cose were used to determine homeostatic model assessment
(HOMA) parameters of insulin resistance using a program
based on the HOMA algorithm (HOMA resistance 
insulin/22.5e-lnglucose), as previously described (12).
Statistical analysis. Results are presented as mean  SD.
Values of p  0.05 were considered statistically significant.
Multigroup comparisons of variables were carried out by
one-way analysis of variance (ANOVA) followed by the
Bonferroni correction. Comparisons of dose-response
curves of parameters during drug infusion were analyzed by
ANOVA for repeated measures by the Bonferroni correc-
tion for multipaired comparisons after adjustment for body
Figure 1. The forearm blood flow (FBF) response to acetylcholine (ACh) in low body mass index (BMI), normal, obese, and extremely obese subjects after
adjustment for body weight.
Figure 2. The forearm blood flow (FBF) response to isosorbide dinitrate (ISDN) in low body mass index (BMI), normal, obese, and extremely obese
subjects after adjustment for body weight.
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weight (Figs. 1 to 3). Relationship between variables were
determined by a spline fit. The data were processed using
either the software package StatView IV (SAS Institute,
Cary, North Carolina), Super ANOVA (Abacus Concepts,
Berkeley, California), or SAS version 8.02 (SAS Institute
Inc.).
RESULTS
Clinical characteristics. The baseline clinical characteris-
tics of the 15 low BMI, 51 normal, 14 obese, and 7
extremely obese individuals are summarized in Table 1. The
BMI was significantly higher between the groups in the
following order: extremely obese  obese  lean  low
BMI. Plasma concentrations of 8-OHdG and serum con-
centrations of MDA-LDL, indexes of oxidative stress, were
significantly higher in the low BMI, obese, and extremely
obese subjects than in normal BMI subjects and were similar
among the low BMI, obese, and extremely obese groups.
Serum concentrations of insulin were significantly higher in
the extremely obese group than in the other three groups.
Homeostatic model assessment resistance was significantly
higher in the extremely obese group than in the low BMI,
normal, and obese groups (3.34 0.56 vs. 1.78 0.31, 1.89
 0.24, and 2.01 0.37, respectively; p 0.05, for all) and
Figure 3. The forearm blood flow (FBF) response to acetylcholine (ACh) in the presence of NG-monomethyl-L-arginine (L-NMMA) in low body mass
index (BMI), normal, obese, and extremely obese subjects after adjustment for body weight.
Table 1. Clinical Characteristics of Low BMI, Normal, Obese, and Extremely Obese Subjects
Variables Low BMI (n  15) Normal (n  51) Obese (n  14) Extremely Obese (n  7)
BMI (kg/m2) 17.9  0.5 22.9  1.8* 27.5  1.4*† 34.6  3.7*†‡
Systolic BP (mm Hg) 116.6  8.2 114.1  11.8 121.3  6.5 118.4  15.4
Diastolic BP (mm Hg) 67.6  6.7 65.8  6.8 67.5  4.2 66.1  8.8
Heart rate (beats/min) 64.2  7.3 65.6  6.7 64.7  6.4 70.4  8.7
Total cholesterol (mmol/l) 5.08  0.69 5.16  0.84 5.19  0.81 5.27  0.87
Triglycerides (mmol/l) 1.18  0.56 1.28  0.65 1.34  0.57 1.46  0.93
HDL cholesterol (mmol/l) 1.41  0.40 1.33  0.42 1.39  0.43 1.36  0.39
LDL cholesterol (mmol/l) 3.51  0.55 3.63  0.69 3.47  0.58 3.77  0.72
Serum glucose (mmol/dl) 4.9  0.4 5.0  0.6 5.2  0.6 5.1  0.7
Serum insulin (pmol/l) 55.3  11.8 58.9  11.7 60.5  13.3 87.9  20.3*
Plasma NOx (mol/l) 24.3  11.7 21.8  13.5 30.2  18.3 26.2  17.8
Plasma norepinephrine (pmol/l) 1.44  0.81 1.57  0.97 1.52  0.76 1.78  0.89
Plasma endothelin-1 (pg/ml) 1.9  0.3 1.8  0.4 1.7  0.2 2.1  0.5
Plasma angiotensin II (pg/ml) 14.3  8.6 13.9  6.8 15.3  7.6 16.5  9.1
Plasma 8-OHdG (ng/ml) 2.76  1.42† 1.14  0.80 2.44  1.65† 3.91  2.36†
Serum MDA-LDL 76.5  30.2† 58.8  21.2 79.6  25.7† 83.4  29.7†
FBF (ml/min/100 ml tissue) 4.2  1.2 4.7  1.3 4.6  1.3 4.3  1.3
FVR (mm Hg/ml/min/100 ml tissue) 19.5  3.7 17.5  4.1 18.6  3.6 19.3  4.3
All results are presented as mean  SD. *p  0.05 vs low BMI; †p  0.05 vs. normal; ‡p  0.05 vs. obese.
BMI  body mass index; FBF  forearm blood flow; FVR  forearm vascular resistance; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MDA-LDL 
malondialdehyde-modified low-density lipoprotein; NOx  nitrite/nitrate; 8-OHdG  8-hydroxy-2-deoxyguanosine.
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were similar between the other three groups. The other
parameters such as plasma NOx, angiotensin II,
endothelin-1, norepinephrine, and serum glucose were sim-
ilar in all four groups.
ACh- and ISDN-induced vasodilation. The intra-arterial
infusion of ACh significantly increased FBF in a dose-
dependent manner in all groups. The response of FBF to
ACh was significantly greater in the normal group than in
the other three groups (p  0.001) and was lower in
extremely obese subjects than in the other three groups (p
0.001) (Fig. 1). The vasodilatory effect of ACh was similar
in the low BMI and obese groups (Fig. 1). The intra-arterial
infusion of ISDN significantly increased FBF in a dose-
dependent manner in all groups. This response was similar
in the four groups (Fig. 2). No significant change was
observed in the arterial BP or heart rate with the intra-
arterial infusion of either ACh or ISDN in any group.
Effects of L-NMMA on the FBF response to ACh. The
intra-arterial infusion of the NO synthase inhibitor,
L-NMMA, decreased basal FBF in all groups. Changes in
the basal forearm vascular responses to L-NMMA infusion
were similar in the four groups. The L-NMMA infusion
also decreased the FBF response to ACh infusion in all
groups. There was no significant difference in the change in
FBF response to ACh after L-NMMA infusion between
the groups (Fig. 3). No significant changes in arterial BP or
heart rate were detected during the infusion of L-NMMA
in any group.
Effects of vitamin C on the FBF response to ACh. Co-
infusion of vitamin C augmented the FBF response to ACh
in low BMI (maximal FBF, 24.2  5.1 vs. 30.1  4.9
ml/min per 100 ml; p 0.01), obese (maximal FBF, 20.3
3.6 vs. 29.7  5.2 ml/min per 100 ml; p  0.01), and
extremely obese groups (maximal FBF, 12.6  3.1 vs. 23.1
 4.8 ml/min per 100 ml; p  0.01), but not in the normal
BMI group (maximal FBF, 38.1  7.3 vs. 41.2  7.1
ml/min per 100 ml; p  0.56; Fig. 4). No significant
change was observed in the arterial BP or heart rate with
the intra-arterial infusion of ACh in combination with
vitamin C.
Figure 4. The effect of concomitant administration of the antioxidant, vitamin C, on the forearm blood flow (FBF) response to acetylcholine (ACh)
administration in low body mass index (BMI), normal, obese, and extremely obese subjects.
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DISCUSSION
In the present study, we demonstrated that endothelium-
dependent vasodilation of forearm resistance artery is im-
paired not only in obese individuals but also in individuals
with a low BMI compared with normal BMI individuals.
This impairment is due to reduced bioavailiability of NO.
The 8-OHdG and MDA-LDL concentrations, indexes of
oxidative stress, significantly increased in the low BMI and
obese groups compared with the normal BMI group.
Vitamin C augmented the FBF response to ACh in low
BMI, obese, and extremely obese groups, but not in the
normal BMI group.
Endothelial function in subjects with a low BMI. In the
present study, we selected healthy and relatively young men
(mean age, 27  5 years; range, 20 to 41 years) to avoid
confounding factors such as atherosclerosis, hypertension,
hypercholesterolemia, diabetes mellitus, aging, smoking,
and menstrual cycle, which alter endothelium-dependent
vasodilation. Endothelium-dependent vasodilation, but not
endothelium-independent vasodilation, was impaired to a
similar degree in low BMI and obese subjects and was
impaired to a greater extent in extremely obese subjects
through the reduced availability of NO. This indicates
selective impairment of the L-arginine-NO pathway rather
than a generalized reduction in vascular smooth muscle cell
response to NO in subjects with a low BMI as well as in
obese individuals. It is generally accepted that endothelium-
dependent vasodilation in the forearm, renal, femoral, and
coronary resistance arteries is selectively impaired as a
characteristic of numerous vascular diseases (10,11,13–16).
Alterations in endothelial function comprise an initial
step in the pathogenesis of arteriosclerosis, leading to an
increased incidence of cardiovascular and cerebrovascular
diseases in these subjects (17). Our results support the
findings of epidemiologic studies that suggest a J-curve
phenomenon, which peaks at a BMI of 22.2 kg/m2, exists
between disease morbidity, including cardiovascular disease,
and BMI (9). Although the relationship between low BMI
and cardiovascular morbidity and mortality is controversial,
several studies have shown that not only overweight but also
lean (low BMI) increases risk of cardiovascular mortality
(18,19). Interestingly, lean hypertensive patients have a
higher cardiovascular mortality rate than do other hyper-
tensive patients (20). A low BMI was found to be an
independent risk factor for death and stroke in the Systolic
Hypertension in the Elderly Program (21).
Mechanisms of impaired endothelium-dependent vaso-
dilation in subjects with a low BMI. In the present study,
there were no significant differences in ACh-stimulated
vasodilation between the four groups, including the low
BMI group, after L-NMMA infusion, suggesting that a
reduced bioavailability of NO may be involved in the
impairment of endothelium-dependent vasodilation in low
BMI subjects.
Interestingly, 8-OHdG, one of the most commonly used
markers for evaluation of oxidative DNA damage, was
significantly increased in the low BMI, obese, and extremely
obese groups compared with the normal group. The
8-OHdG is a specific product formed by the attack of a
hydroxy radical on DNA (22). Several studies suggest that
the oxidative DNA damage is increased in non–insulin-
dependent diabetes mellitus and aging (23,24). The MDA-
LDL also is an index of oxidative stress (25–27). The
measurement of MDA-LDL has been proposed as the
biologic signature of clinical in vivo LDL oxidation (25,26).
Maggi et al. (27) have recently reported that serum MDA-
LDL concentration is higher in essential hypertensive pa-
tients than in normal controls. Other experimental and
clinical studies have shown that oxidative stress is strongly
implicated in endothelial dysfunction (28–31). Rubanyi et
al. (30) demonstrated that superoxide radicals suppress
endothelium-dependent vasodilation induced by ACh in
the canine coronary artery. Mugge et al. (31) have shown
that ACh-stimulated vasodilation is attenuated after the
inhibition of antioxidant defense systems. Superoxide radi-
cals, including hydroxy radicals, directly scavenge NO and
produce toxic peroxynitrite (32). A balance between ambi-
ent levels of superoxide and released NO plays a crucial role
in the maintenance of normal endothelial function. In the
present study, endothelium-dependent vasodilation was at-
tenuated despite unchanged NO production in low BMI,
obese, and extremely obese individuals, suggesting that
decreased availability of NO could be due to its degradation
by superoxide radicals rather than decreased NO produc-
tion. In addition, vitamin C, an antioxidant, augmented the
FBF response to ACh in low BMI, obese, and extremely
obese groups. These findings suggest that oxidative stress
may be, at least in part, involved in impaired endothelium-
dependent, NO-mediated vasodilation in subjects with a
low BMI as well as obese individuals. However, the precise
mechanism responsible for increased oxidative stress in low
BMI and obese subjects remains unknown.
In the present study, endothelium-dependent vasodila-
tion was impaired in obese individuals, and impaired to the
greater degree in extremely obese individuals. These results
are consistent with previous studies that demonstrate that
obesity is associated with endothelial dysfunction (6,7,33).
The degree of HOMA impairment, an index of insulin
resistance, was greater in the extremely obese group than in
the other three groups. Obesity is a major cause of insulin
resistance in humans. Recently, Steinberg et al. (6) demon-
strated that methacholine-induced increases in leg blood
flow were approximately 40% lower in obese insulin resis-
tance subjects (BMI28 kg/m2) than normal BMI insulin-
sensitive controls (BMI 28 kg/m2). These findings sug-
gest that obesity-related insulin resistance is associated with
endothelium-dependent vasodilation. In the present study,
8-OHdG tended to be higher, although not significantly, in
the extremely obese group than in the low BMI and obese
groups. Therefore, oxidative stress, in combination with an
increase in insulin resistance, may contribute to the greater
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attenuation of endothelium-dependent vasodilation in ex-
tremely obese individuals.
A balance of vasodilators and vasoconstrictors plays an
important role in the physiologic regulation of vascular tone
(1–3). It is well known that various vasoconstricting factors
released from endothelium, such as angiotensin II and
endothelin-1, affect endothelium-dependent vasodilation in
humans. We have confirmed that circulating levels of both
angiotensin II and endothelin-1 are similar between the low
BMI, normal, obese, and extremely obese groups. However,
we cannot deny the possibility that other vasoconstrictors
contribute to differences in the degree of ACh-stimulated
vasodilation.
Previous studies have shown that autonomic dysfunction,
especially sympathetic dysfunction, occurs in obese individ-
uals (34,35). Norepinephrine, which acts as a potent vaso-
constrictor, attenuates endothelium-dependent vasodila-
tion. However, plasma norepinephrine concentrations were
similar when low BMI, normal, obese, and extremely obese
subjects were compared. Therefore, the differences in FBF
response to ACh between the four groups cannot be
explained by differences in sympathetic nervous system
activity.
Study limitations. In the present study, we focused on the
relationship between BMI, especially low BMI, and endo-
thelial function and showed that endothelium-dependent
vasodilation is distinguished in low BMI individuals
through increases in oxidative stress. However, the mecha-
nisms responsible for alterations in endothelial function are
varied and multifactorial. Further studies are needed to
address the other mechanisms of endothelial dysfunction.
In the present study, the number of subjects is relatively
small compared with large epidemiologic trials. A larger
sample size of subjects may show more specific conclusions.
It is well known that lifestyle characteristics, including
aerobic exercise, diet, smoking, sodium intake, and alcohol
intake influence endothelial function. We consider that the
lifestyle characteristics of all the subjects in our study were
almost the same because most of the subjects were students
of the Hiroshima University. However, the possibility that
differences in lifestyle characteristics affected the FBF re-
sponse to ACh cannot be ruled out.
Conclusions. Our results suggest that not only obesity, but
also a low BMI, is a risk factor for impaired endothelium-
dependent vasodilation in humans through increased oxida-
tive stress, leading to the reduced bioavailability of NO.
Endothelial dysfunction is an early finding in the pathogen-
esis of arteriosclerosis, leading to increases in the incidence
of cardiovascular complications. A low BMI may be an
additional risk factor for cardiovascular disease. Studies
defining the relationship between BMI and endothelial
function in the setting of arteriosclerosis, hypercholesterol-
emia, hypertension, diabetes mellitus, and heart failure in
which endothelium-dependent vasodilation is impaired
would be of great interest.
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